Sephience now carries the story
- Sephience became PTC's lead product in Q1 2026, with $125 million in revenue.
- The 2026 product revenue guide rose to $750 million to $850 million after the strong launch.
- The older Duchenne muscular dystrophy drugs are fading, with Emflaza facing 10 generics.
- Vatiquinone is still alive, but the new study needs 24 months of follow-up before it can support a new FDA filing.
- Cash of $1.89 billion gives PTC time, but the stock still depends on Sephience staying strong.
A launch-led turnaround
PTC has become a Sephience story. The PKU drug brought in $125 million of Q1 2026 revenue, including $112 million in the U.S. Management also pointed to about 140 U.S. starts per month and an early Japan launch. That pushed 2026 product revenue guidance up to $750 million to $850 million.
The bull case is simple. If Sephience keeps this pace, it can more than offset the decline in the old Duchenne muscular dystrophy business and move PTC closer to profit. The company also has $1.89 billion in cash, which gives it time to fund launches and research.
The bear case is concentration. PTC now leans hard on one new drug. Translarna depends more on uneven government orders after losing key European access. Emflaza is under pressure from 10 generics. Vatiquinone also moved further out, because the new study uses a 24-month endpoint.
Votoplam adds longer-term upside. The Huntington's disease program showed 52% slowing of disease progression against a matched natural history group at 24 months, and Novartis is running a major Phase III study. That helps the future story, but it does not fix the near-term need for Sephience execution.
Rare disease drugs, launch risk
PTC makes money mainly by selling rare disease drugs. Its key products are Sephience, Translarna, Emflaza, and Upstaza or Kebilidi. It also can earn collaboration revenue, such as upfront payments and milestones from partners.
This model can work well when a drug reaches a small patient group with few good options. Prices can be high, and the sales force can be focused. But it breaks when a drug loses exclusivity, loses market access, or fails to win approval.
PTC has a long history of losses and has used stock sales, convertible debt, partnerships, and royalty sales to fund itself. As of December 2025, it had sold 100% of its Evrysdi royalty rights to Royalty Pharma. That brought cash in, but it also removed a future royalty stream.
The next test is not whether PTC can discover rare disease drugs. It is whether Sephience can stay large enough, and profitable enough, to replace falling DMD revenue while the pipeline matures.
What PTC sells and studies
Sephience
Sephience treats phenylketonuria, or PKU, a rare inherited disorder that causes harmful buildup of phenylalanine. It is approved in the U.S., EEA, Japan, and other regions, and is now PTC's main growth driver.
Translarna
Translarna treats nonsense mutation Duchenne muscular dystrophy outside the U.S. and EEA. Sales are under pressure after the EEA authorization was not renewed, and recent revenue included a large one-time Brazil government order.
Emflaza
Emflaza treats Duchenne muscular dystrophy in the U.S. Its main orphan drug exclusivity ended in February 2024, and 10 generics are now on the market.
Upstaza and Kebilidi
This gene therapy treats AADC deficiency, a very rare nervous system disorder. It is approved in the EEA, UK, and U.S., with Kebilidi as the U.S. brand.
Tegsedi and Waylivra
PTC licenses these medicines for commercialization in Latin America. They add breadth, but they are not the main driver of the current thesis.
Vatiquinone
Vatiquinone is being developed for Friedreich ataxia. After an FDA complete response letter in August 2025, PTC plans a new open-label study with a 24-month primary endpoint.
Votoplam
Votoplam, also called PTC518, targets Huntington's disease through RNA splicing. Positive 24-month data, including 52% slowing versus a matched natural history group, support the partnered Novartis Phase III program.
Q1 mix is now Sephience-heavy
PTC reports as one segment, so this mix uses Q1 2026 net product revenue by product. Sephience was already more than half of product sales, which makes the launch ramp the key watch item.
What could go wrong
Sephience launch slows
High impact · Medium oddsPTC's growth story now depends on Sephience. If U.S. starts fall below the recent level of about 140 per month, or if international launches come in at lower prices than expected, revenue and margins could disappoint.
DMD revenue falls faster
High impact · High oddsEmflaza faces 10 generics after losing key exclusivity. Translarna no longer has EEA authorization and depends more on markets such as Brazil and Russia, where orders can be large but uneven.
Vatiquinone stays delayed
Medium impact · High oddsThe FDA issued a complete response letter for vatiquinone in August 2025. PTC now plans a study with a 24-month endpoint, which pushes any likely resubmission into 2028 or later.
Cash runway is misread
Medium impact · Medium oddsPTC has $1.89 billion in cash, which is a strong buffer. But the company also has a history of losses, and it has sold 100% of the Evrysdi royalty stream. Future profitability still depends on product sales, not the old royalty income.
Votoplam Phase III fails
Medium impact · Medium oddsVotoplam has encouraging 24-month data, but it still needs Phase III proof in Huntington's disease. A failure would remove a major long-term option, even though Novartis carries much of the development path.
In one breath
What is PTC Therapeutics best known for now?
PTC is now best known for Sephience, its PKU drug. In Q1 2026, Sephience brought in $125 million and became the company's lead product.
Why are Translarna and Emflaza a problem?
Both are older Duchenne muscular dystrophy products with falling durability. Translarna lost EEA authorization, while Emflaza faces 10 generics after its main orphan drug exclusivity expired.
Does PTC still get Evrysdi royalties?
No. As of December 2025, PTC sold 100% of its Evrysdi royalty rights to Royalty Pharma, trading future royalties for upfront cash.
What is the next big pipeline event?
The most important near-term pipeline step is starting the new vatiquinone study. The main long-term option is votoplam in Huntington's disease, where Novartis is running a Phase III program.